View in EDS HTML Full Text PDF Full Text

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.

Saved in:
Bibliographic Details
Title: Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
Authors: Ferrante, Marc1 (AUTHOR) marc.ferrante@uzleuven.be, Feagan, Brian G2 (AUTHOR), Panés, Julián3 (AUTHOR), Baert, Filip4 (AUTHOR), Louis, Edouard5 (AUTHOR), Dewit, Olivier6 (AUTHOR), Kaser, Arthur7 (AUTHOR), Duan, W Rachel8 (AUTHOR), Pang, Yinuo8 (AUTHOR), Lee, Wan-Ju8 (AUTHOR), Gustafson, Dawn8 (AUTHOR), Liao, Xiaomei8 (AUTHOR), Wallace, Kori8 (AUTHOR), Kalabic, Jasmina9 (AUTHOR), D'Haens, Geert R10 (AUTHOR)
Source: Journal of Crohn's & Colitis. Dec2021, Vol. 15 Issue 12, p2001-2010. 10p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:18739946
DOI:10.1093/ecco-jcc/jjab093